Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

• Authors: Aldona Pietrzak , Jerzy Mosiewicz , Grażyna Chodorowska , Anna Brzozowska , Anna Michalak-Stoma , Justyna Szumiło , Marcin Trojnar , Dorota Krasowska , Bartłomiej Wawrzycki , Kinga Franciszkiewicz-Pietrzak , Wojciech Polkowski , Torello Lotti
• Languages of publication: EN

Abstracts

EN

The article focuses on the eruption of palmoplantar pustular psoriasis, which was documented in a 53-year-old man diagnosed with prostate cancer with bone metastases. This clinical finding was made during routine hormone therapy and palliative radiotherapy. The local improvement in skin lesions was achieved following administration of topical ointments and the use of UVA 311 nm radiation therapy. The management of prostate cancer in this subject resulted in malaise, onset of diabetes mellitus and increased concentration of serum lipids. Interestingly, a few days after the statin treatment was initiated, the intensive pustule eruption was observed as well as severe pain and burning sensation in the palms and soles. The dermatological treatment led to significant improvement. The patient is still receiving oncological therapy and is monitored by dermatologists on a regular basis.

Keywords

EN

Psoriasis; Prostate cancer; Hormone therapy; Statin

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 5
• Pages: 657-662

Dates

published

1 - 10 - 2014

online

31 - 7 - 2014

Contributors

author

Aldona Pietrzak

• Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, 20-080, Lublin, Poland

author

Jerzy Mosiewicz

• Chair and Department of Internal Medicine, Medical University of Lublin, 20-080, Lublin, Poland

author

Grażyna Chodorowska

• Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, 20-080, Lublin, Poland

author

Anna Brzozowska

author

Anna Michalak-Stoma

• Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, 20-080, Lublin, Poland

author

Justyna Szumiło

author

Marcin Trojnar

• Chair and Department of Internal Medicine, Medical University of Lublin, 20-080, Lublin, Poland

author

Dorota Krasowska

• Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, 20-080, Lublin, Poland

author

Bartłomiej Wawrzycki

• Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, 20-080, Lublin, Poland

author

Kinga Franciszkiewicz-Pietrzak

• Department of Surgery, Medical University of Lublin, 20-080, Lublin, Poland

author

Wojciech Polkowski

• Chair and Department of Oncologic Surgery, Medical University of Lublin, 20-080, Lublin, Poland

author

Torello Lotti

• Chair and Department of Dermatology and Venereology, University of Rome“G. Marconi”, Rome, Italy

References

• [1] Paul CF, Ho VC, McGeown C, et al. Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study. J Invest Dermatol. 2003;120:211–216 http://dx.doi.org/10.1046/j.1523-1747.2003.12040.x[Crossref]
• [2] Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778–783
• [3] Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4:579–594 http://dx.doi.org/10.1002/pros.2990040605[Crossref]
• [4] Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer. 2011;2:145–156 http://dx.doi.org/10.1007/s12672-010-0063-1[Crossref]
• [5] Muehlenbein MP, Bribiescas RG. Testosteronemediated immune functions and male life histories. Am J Hum Biol. 2005;17:527–558 http://dx.doi.org/10.1002/ajhb.20419[Crossref]
• [6] Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411–423 http://dx.doi.org/10.1093/humupd/dmi008[Crossref]
• [7] Fitzpatrick F, Lepault F, Homo-Delarche F, Bach JF, Dardenne M. Influence of castration, alone or combined with thymectomy, on the development of diabetes in the nonobese diabetic mouse. Endocrinology. 1991;129:1382–1390 http://dx.doi.org/10.1210/endo-129-3-1382[Crossref]
• [8] Harbuz MS, Perveen-Gill Z, Lightman SL, Jessop DS. A protective role for testosterone in adjuvant-induced arthritis. Br J Rheumatol. 1995;34:1117–1122 http://dx.doi.org/10.1093/rheumatology/34.12.1117[Crossref]
• [9] Ahmed SA, Penhale WJ. The influence of testosterone on the development of autoimmune thyroiditis in thymectomized and irradiated rats. Clin Exp Immunol. 1982;48:367–374 [PubMed]
• [10] Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med. 1992;175:1409–1412 http://dx.doi.org/10.1084/jem.175.5.1409[Crossref]
• [11] Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in theautoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6
• [12] Ansar Ahmed S, Young PR, Penhale WJ. Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol. 1986;136:143–147
• [13] Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–593 http://dx.doi.org/10.1038/nri2817[Crossref]
• [14] Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol. 2010;71:496–504 http://dx.doi.org/10.1016/j.humimm.2010.02.007[WoS][Crossref]
• [15] Norata GD, Cattaneo P, Poletti A, Catapano AL. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Atherosclerosis. 2010;212:100–106 http://dx.doi.org/10.1016/j.atherosclerosis.2010.05.015[Crossref]
• [16] Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharideinduced inflammatory response in human endothelial cells. J Clin Endocrinol Metab. 2006;91:546–554 http://dx.doi.org/10.1210/jc.2005-1664[Crossref]
• [17] Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602–612 http://dx.doi.org/10.1111/j.1365-2265.2010.03845.x[Crossref][WoS]
• [18] Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, Kawasaki T, Takahashi K. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. Prostate. 2012;72:1207–1213 http://dx.doi.org/10.1002/pros.22471[Crossref][WoS]
• [19] Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis. 1998;1:307–314 http://dx.doi.org/10.1038/sj.pcan.4500262[Crossref]
• [20] Ziółkowska E, Biedka M, Żyromska A, Makarewicz R. Psoriasis exacerbation after hormonotherapy in prostate cancer patient - Case report. Rep Pract Oncol Radiother. 2010;15:103–106 http://dx.doi.org/10.1016/j.rpor.2010.03.003[Crossref]
• [21] Honma M, Takahashi H, Horikawa M, Iizuka H. Palmoplantar Pustular Lesions during Ovulation Inducement Therapy: New Insight into the Pathomechanism of Palmoplantar Pustulosis? Dermatology. 2009;218:382–384 http://dx.doi.org/10.1159/000182262[WoS][Crossref]
• [22] Egesi A, Sun G, Khachemoune A, Rashid RM. Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol. 2010;9:921–927 [PubMed]
• [23] Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J. 2010;16:2 [PubMed]
• [24] Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol. 2007;57:529–531 http://dx.doi.org/10.1016/j.jaad.2007.05.040[Crossref]
• [25] Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol. 1988;124:854–855 http://dx.doi.org/10.1001/archderm.1988.01670060012006[Crossref]
• [26] Cozzani E, Scaparro M, Parodi A. A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009;3:60–61 http://dx.doi.org/10.1186/1752-1947-3-60[Crossref]
• [27] Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149:1305–1306 http://dx.doi.org/10.1111/j.1365-2133.2003.05675.x[Crossref]

Identifiers

DOI

10.2478/s11536-013-0310-2